Life Biosciences announced a research collaboration with the Regenerative Medicine Institute of Singapore (REMEDIS), part of SingHealth Duke-NUS Academic Medical Centre, to expand its pipeline of cellular rejuvenation therapies, according to the company.
The collaboration will combine Life Biosciences’ expertise in cellular rejuvenation with REMEDIS’ capabilities in regenerative medicine and translational research. The company said that the partnership aims to identify and develop new therapeutic candidates to address age-related diseases and degenerative conditions.
Life Biosciences focuses on restoring cell health and function by reversing age-related cellular damage. The company claims this approach could lead to treatments that improve quality of life for patients affected by conditions driven by cellular aging.
REMEDIS will provide research infrastructure and scientific expertise to support the joint discovery and preclinical development programs. The company said the collaboration will target multiple disease areas where cellular rejuvenation may offer clinical benefit.
Life Biosciences also noted that the partnership aligns with its strategy to work with global academic and clinical institutions to accelerate research and bring new therapies to market. The company claims the collaboration could strengthen its existing pipeline by adding new candidates identified through shared research efforts.
The partnership reflects growing international interest in translating cellular rejuvenation science into therapeutic applications aimed at treating age-related and degenerative diseases, according to the company.
